Literature DB >> 8839828

The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.

J V Melo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839828

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  126 in total

Review 1.  Clinical applications of BCR-ABL molecular testing in acute leukemia.

Authors:  Amgad L Nashed; Kathleen W Rao; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.

Authors:  Nathalie Sorel; Caroline Mayeur-Rousse; Séverine Deverrière; Lydia Roy; Elisabeth Brottier-Mancini; François Guilhot; Ali G Turhan; Jean Claude Chomel
Journal:  J Mol Diagn       Date:  2010-05-27       Impact factor: 5.568

3.  No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Authors:  Markus Pfirrmann; Dobromira Evtimova; Susanne Saussele; Fausto Castagnetti; Francisco Cervantes; Jeroen Janssen; Verena S Hoffmann; Gabriele Gugliotta; Rüdiger Hehlmann; Andreas Hochhaus; Joerg Hasford; Michele Baccarani
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-12       Impact factor: 4.553

4.  A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.

Authors:  K Okuda; A D'Andrea; R A Etten; J D Griffin
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

5.  Molecular characterization of canine BCR-ABL-positive chronic myelomonocytic leukemia before and after chemotherapy.

Authors:  Sarah Culver; Daisuke Ito; Luke Borst; Jerold S Bell; Jaime F Modiano; Matthew Breen
Journal:  Vet Clin Pathol       Date:  2013-06-25       Impact factor: 1.180

6.  Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.

Authors:  Anand P Singh; Michael S Glennon; Prachi Umbarkar; Manisha Gupte; Cristi L Galindo; Qinkun Zhang; Thomas Force; Jason R Becker; Hind Lal
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

7.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 8.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 9.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

10.  An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia.

Authors:  Sara Raponi; Maria Stefania De Propris; Hobert Wai; Stefania Intoppa; Loredana Elia; Daniela Diverio; Antonella Vitale; Robin Foà; Anna Guarini
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.